Newsroom | 199021 results

Sorted by: Latest

Health
-

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrela...
-

Earnings Teleconference Moves to Earlier Time on July 29

--(BUSINESS WIRE)--UNH Earnings Teleconference Moves to Earlier Time on July 29...
-

NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation

GLASSBORO, N.J.--(BUSINESS WIRE)--Two transformative healthcare announcements mark a new era for New Jersey’s innovation economy—with GSVP emerging as a key catalyst behind both....
-

Sun Nuclear to Highlight New Quality Management Solutions at 2025 AAPM Annual Meeting

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will present significant additions to its comprehensive portfolio of Radiation Therapy Quality Management solutions at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting, taking place July 27-29, in Washington, D.C. Attendees are invited to explore new software and hardware innovations designed to help elevate treatment quality, streamline workflows, and support safer care. Premiering at AAPM 202...
-

MedX Announces Proposed Non-Brokered Private Placement to Raise up to $2,500,000 and Stock Option Grants

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing to raise up to $2,500,000 by way of a Non-Brokered Private Placement of up to 33,333,334 Units at $0.075 per Unit (“Unit”). Each Unit will be comprised of One (1) fully paid common share and One-half (1/2) of a Share Purchase Warrant; each whole Share Purchase Warrants (“Warrant(s)”) will be exercisable to purchase One (1) further Common Share at the price...
-

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company’s common stock and...
-

Omega Announces Quarterly Dividend

HUNT VALLEY, Md.--(BUSINESS WIRE)--Omega Healthcare Investors, Inc. (NYSE:OHI) today announced that the Company’s Board of Directors declared a cash dividend of $0.67 per share on its common stock. The dividend is payable Friday, August 15, 2025, to common stockholders of record as of the close of business on Monday, August 4, 2025. Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfoli...
-

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balst...
-

Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause...
-

HOMELINK Adds New Director to Lead Provider Network Development & Relations

WATERLOO, Iowa--(BUSINESS WIRE)--HOMELINK, a leading provider of integrated specialty services for workers’ compensation and group health, is pleased to announce the addition of Derek Ferrell as director of provider network development and relations. He brings deep expertise in network development and enhancement, contract and claims negotiation, and network operations to the company. “Derek’s wealth of experience and fresh perspective will be key to further building our top-tier national netwo...